Botulinum toxin type A showed no clear difference in adverse events: dysphagia № of participants: 249 (3 RCTs) compared with botulinum toxin type B (low certainty).
Botulinum toxin type A showed no clear difference in participants with adverse events № of participants: 111 (1 RCT) compared with botulinum toxin type B (low certainty).
Botulinum toxin type A probably leads to higher adverse events: sore throat/dry mouth № of participants: 212 (2 RCTs) compared with botulinum toxin type B (moderate certainty).
The review found no eligible studies for this question.
Botulinum toxin A showed no clear difference in adverse events compared with placebo (low certainty).
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
It is very uncertain whether botulinum toxin type A changes tolerability assessed by dropouts due to adverse events compared with anticholinergics (very low certainty).
Botulinum toxin type A showed no clear difference in adverse events (reported at any time) (2 RCT, 169 participants) compared with placebo (low certainty).
Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in total adverse events compared with onabotulinumtoxinA 20U (moderate certainty).
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes major adverse events compared with onabotulinumtoxinA 24U (very low certainty).
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes total adverse events compared with onabotulinumtoxinA 24U (very low certainty).
It is very uncertain whether botulinum toxin plus conservative treatment changes adverse events compared with conservative treatment only (very low certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events ‐ Any major adverse events (eyelid ptosis,… compared with onabotulinumtoxinA 20U (moderate certainty).
Botulinum neurotoxin B leads to higher adverse events: dry mouth compared with placebo (high certainty).